Overview


According to FutureWise analysis, the market for Anti-suicide drugs is expected to reach US$ 0.01 billion by 2031 at a CAGR of 4.2% over the forecast period of 2023-2031.

Suicide is the act of intentionally taking one's own life. It is a complex and tragic phenomenon often driven by a combination of psychological, social, cultural, and environmental factors. People who contemplate or commit suicide may be experiencing overwhelming emotional pain, despair, hopelessness, and a perceived inability to cope with their circumstances. Suicidal thoughts and behaviors can be significantly influenced by mental health issues like depression, bipolar disorder, anxiety, and substance abuse. It is essential to address and prevent suicide by providing mental health support, increasing awareness, and intervening when necessary. If you or someone you know is struggling with suicidal thoughts, it is crucial to seek help immediately from a mental health professional, counselor, or helpline.

Anti-suicide drugs, or suicide prevention medications, are pharmaceutical interventions to mitigate the underlying mental health conditions contributing to suicidal thoughts and actions. These medications include antidepressants that regulate neurotransmitters like serotonin to alleviate depressive symptoms, antipsychotics that manage psychosis and stabilize mood, mood stabilizers like lithium for bipolar disorder-related mood swings, and emerging options like ketamine with rapid-acting antidepressant effects. For instance, consider an individual grappling with severe depression and persistent suicidal thoughts. Following a mental health professional consultation, they are prescribed an SSRI like fluoxetine. As the medication takes effect, their mood gradually improves, and the intensity of suicidal ideation diminishes. This reduction in distressing symptoms enables the person to engage more effectively in therapy and develop coping strategies, forming a comprehensive approach to address their mental health challenges and minimize the risk of suicide.

FutureWise Market Research has published a report that provides an insightful analysis of Anti-Suicide Drugs Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Anti-Suicide Drugs Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Pfizer, Inc.
  • Johnson & Johnson
  • Eli Lilly and Company
  • Allergan plc
  • GlaxoSmithkline plc
  • AstraZeneca plc
  • Merck & Co., Inc.
  • H. Lundbeck A/S
  • NeuroRx, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Development in Anti-Suicide Drugs Market:

  • In August 2022, the U.S. FDA approved dextromethorphan-bupropion, known as Auvelity and developed by Axsome Therapeutics, to treat major depressive disorder in adults. Notably, this medication is the first to exhibit effectiveness within a week of administration. 
  • In April 2022, pharmaceutical company Lundbeck's antidepressant vortioxetine, commercially available as Trintellix and Brintellix, showcased a notable advantage in a direct comparison study against desvenlafaxine, marketed as Pristiq by Pfizer in the United States. The study focused on evaluating vortioxetine's efficacy among individuals diagnosed with Major Depressive Disorder (MDD) who had shown only partial improvement in response to selective serotonin reuptake inhibitors (SSRIs); a comparison was conducted to evaluate the effects of vortioxetine against those of desvenlafaxine.

The anti-suicide drug market is driven by factors that shape its dynamics. The escalating awareness surrounding mental health issues plays a vital role in driving the demand for anti-suicide drugs. As societies become more accepting of discussing mental health openly, the stigma around seeking help for suicidal thoughts diminishes, encouraging individuals to seek treatment proactively. Initiatives such as awareness campaigns and prominent figures sharing their struggles contribute to this positive shift. Concurrently, the alarming surge in global suicide rates acts as a compelling driver, underscoring the urgent need for effective interventions. Governments, organizations, and healthcare providers recognize the gravity of this issue, heightening the demand for anti-suicide drugs as a critical component in combating this crisis.

Moreover, promising opportunities emerge on the horizon. In emerging markets, where mental health awareness is gaining traction, a substantial, yet largely untapped, potential exists for anti-suicide drugs. The gradual breakdown of barriers to discussing mental health in these regions creates a conducive environment for pharmaceutical companies to extend their reach and make a significant impact. Additionally, the paradigm of personalized medicine presents a revolutionary opportunity. Genetic research and biomarker identification advances offer the potential to customize anti-suicide drug treatments based on an individual's genetic profile and biomarker markers. This tailoring could result in higher treatment efficacy, marking a significant advancement in psychiatric care.

However, several significant restraints shape the landscape. Regulatory hurdles marked by stringent clinical trial and approval requirements can delay the introduction of new anti-suicide drugs. While crucial for safety, the meticulous review processes can prolong the time it takes for potentially life-saving medications to reach those in need.

By Drug Class

  • Anti-Depressant and Anti-Anxiety Drugs
  • N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
  • Antibiotic Analog
  • Anti-Psychotic Drugs
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America holds a significant portion of the global anti-suicide drugs market due to factors such as a surge in suicidal incidents and the introduction of a diverse range of anti-suicidal medications. This rise can be attributed to a well-established healthcare system, increased disposable income, and more significant investments in research and development. In the Asia-Pacific region, the Anti-Suicide Drugs market is projected to witness the swiftest growth in the upcoming years. This can be attributed to the region's alarming suicide rates, growing mental health awareness, and rapid healthcare infrastructure enhancements.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the of Anti-Suicide Drugs Market By Drug Class By Distribution Channel and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represents in format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

 

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Anti-Suicide Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anti-Suicide Drugs Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Anti-Suicide Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Anti-Suicide Drugs Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Anti-Depressant and Anti-Anxiety Drugs
        2. N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
        3. Antibiotic Analog
        4. Anti-Psychotic Drugs
        5. Others

  • 8.   Global Anti-Suicide Drugs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies

  • 9.   North America Anti-Suicide Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Anti-Suicide Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Anti-Suicide Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Anti-Suicide Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Anti-Suicide Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Johnson & Johnson
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Eli Lilly and Company
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Allergan plc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GlaxoSmithkline plc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. AstraZeneca plc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. MerckCo., Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. H. Lundbeck A/S
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. NeuroRx, Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients